Dr. Kinneret Savitsky will no longer serve as Chief Executive Officer at BioLine Rx Ltd effective October 10 2016. She has held this role since January 2010. Prior to that she was General Manager of BioLine Innovations Jerusalem Ltd. since 2004. Dr. Savitsky was formerly Vice President Biology Research and Development at Compugen a biotechnology company. She joined Compugen in 1997 as Senior Scientist in Compugen newly founded laboratory and led the company shift from computational genomics to development of diagnostics and therapeutics. She was responsible for all of Compugen drug candidate identification and development as well as experimental biology. At Compugen she managed a team of over 35 scientists and drug developers
Savitsky holds a BS degree in Biology from The Hebrew University of Jerusalem, a MS degree in Human Genetics and a Doctorate of Science degree in Human Genetics, both from TelAviv University.
The company has return on total asset (ROA) of (39.95) % which means that it has lost $39.95 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (77.4) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 44.85 K in total debt. BIOLINE RX LTD has Current Ratio of 3.83 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Kinneret Savitsky Ph.D., 44Chief Exec. Officer327.00KN/AMr. Philip A. Serlin CPA, MBA, 51Chief Financial Officer, Chief Operating Officer, Principal Accounting Officer and Member of Investment Monitoring Committee271.00KN/AProf. Moshe Phillip M.D., 57VP of Medical Affairs, Sr. Clinical Advisor and Member of Scientific Advisory Board291.00KN/ADr. Leah Klapper Ph.D., 47Gen. Mang. of BioLine Innovations Jerusalem237.00KN/A Raziel Fried, Treasurer and Member of Investment Monitoring CommitteeN/AN/ABIOLINE RX LTD (BLNEF) is traded on OTC Market in USA. It is located in , except where noted. and employs 52 people.
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add BIOLINE RX LTD to your portfolio